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HIGHLIGHTS          37 
• Some biological response to E2 displays biphasic dose relationship. 38 
• ERαAF1 plays a key sensitizing role in ERα activity. 39 
• Differences and even contradictory conclusions could be explained by 40 
differences of E2 doses. 41 
 42 
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                                                                                                            57 
ABSTRACT 58 
17β-Estradiol (E2) action can be mediated by the full-length estrogen receptor alpha (ERα66), 59 
but also by the AF1 domain-deficient ERα (ERα46) isoform, but their respective sensitivity 60 
to E2 is essentially unknown. To this aim, we first performed a dose response study using 61 
subcutaneous home-made pellets mimicking either metestrus, proestrus or a pharmacological 62 
doses of E2, which resulted in plasma concentrations around 3, 30 and 600 pM, respectively. 63 
Analysis of the uterus, vagina and bone after chronic exposure to E2 demonstrated dose-64 
dependent effects, with a maximal response reached at the proestrus- dose in wild type mice 65 
expressing mainly ERα66. In contrast, in transgenic mice harbouring only an ERα deleted in 66 
AF1, these effects of E2 were either strongly shifted rightward (10 to 100-fold) and/or 67 
attenuated, depending on the tissue studied. Finally, experiments in different cell lines 68 
transfected with ERα66 or 46 also delineated varying profiles of ERα AF1 sensitivity to E2. 69 
Altogether, this work emphasizes the importance of dose in the tissue-specific actions of E2 70 
and demonstrates the key sensitizing role of AF1 in ERα activity.  71 
 72 
Keywords: Estrogen receptor alpha (ERα), activation function (AF), dose response, tissue-73 
specific 74 
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1. Introduction 76 
During her lifetime, a woman is exposed to varying levels of estrogens. At puberty, 77 
the onset of the menstrual cycle leads to a cyclical production of estrogens with large 78 
fluctuations in estrogen levels. Pregnancy is marked by an extensive increase in estrogens 79 
levels whereas menopause, the consequence of the cessation of estrogen production by 80 
ovaries in women, results in a sharp decrease in the main estrogen 17-β estradiol (E2) levels. 81 
These hormonal variations translate into changes not only in sex targets organs involved in 82 
sex secondary characters and reproduction, but also in many other non-reproductive tissues. 83 
In particular, estrogens play an important role in the growth and maturation of bone as well as 84 
in the regulation of bone turnover in adult. The importance of estrogen for skeletal health is 85 
well known and represents an important research area. Indeed, estrogen deficiency is a major 86 
risk for development of osteoporosis and leads to increased fracture risk, while estrogen 87 
treatment reduces this risk (Almeida et al., 2017). Unfortunately, long-term estrogen therapy 88 
is also associated with serious side-effects, mainly increased risk of breast cancer and of deep 89 
venous thrombosis (Valera et al., 2018).  90 
Mouse models have already contributed to elucidation of the mechanisms of action of 91 
estrogens in vivo (Guillaume et al., 2017; Hewitt and Korach, 2018; Rooney and van der 92 
Meulen, 2017). In general, mice are ovariectomized to eliminate the main source of 93 
endogenous estrogens, and to allow studying the effects of doses of exogenous E2 delivered 94 
by various devices, such as subcutaneous pellets. A large range of pellets that deliver estrogen 95 
from 0.01 mg/pellet (i.e., 0.8 µg/kg/day) to 5 mg/pellet (i.e., 2000 µg/kg/day) are available, 96 
and very different doses are used in the literature, often without justification of the dose 97 
employed. Furthermore, estrogens have frequently been reported to exert a hormetic or 98 
biphasic dose-response relationship, characterized by low-dose stimulation and high-dose 99 
inhibition (Strom et al., 2011; Duarte-Guterman et al., 2015). One example of such a 100 
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dichotomous effect was reported in ischemic stroke; whereas some studies have shown a 101 
neuroprotective effect of estrogen, others have reported neurotoxicity, the differences being 102 
attributed to the dose (Strom et al., 2009).  103 
The different responses to E2 are initiated by their binding to the estrogen receptors 104 
(ERs), ERα and ERβ, which belong to the nuclear receptor superfamily and are structurally 105 
organized into 6 functional domains (A to F). The E domain supports hormone binding, which 106 
induces conformational changes that are required for ER transcriptional activity through the 107 
modulation of two activation functions (AFs), AF1 and AF2, located in the A/B and E 108 
domains, respectively. In addition to the full-length 66-kDa (ERα66) isoform, a 46-kDa ERα-109 
isoform (ERα46), lacking the N-terminal portion (domains A/B), and thereby AF-1, has been 110 
reported to be expressed in various cell types such as human osteoblasts (Denger et al., 2001), 111 
macrophages (Murphy et al., 2009), and vascular endothelial cells (Murphy et al., 2009), but 112 
also in cancer cells (Chantalat et al., 2016). Mechanisms regulating both the expression of 113 
ERα46 and its functions remain essentially unknown. ERα can be generated by either 114 
alternative splicing, proteolysis, or an alternative initiation of translation via an internal 115 
ribosome entry site (IRES) (Chantalat et al., 2016). 116 
ER-mediated transcriptional regulation involves either a direct interaction of ER with 117 
specific estrogen-responsive elements (EREs) located in enhancers or near the promoter 118 
region of target genes, or an indirect mechanism (tethered) via protein/protein interactions 119 
with other transcriptional factors (Hamilton et al., 2017). ERαAF1 and ERαAF2 have been 120 
shown to play crucial roles in the transcriptional effects of ERα through the recruitment of 121 
coactivators. In cultured cells, the respective roles of ERαAF1 and ERαAF2 appear to depend 122 
on the state of cell differentiation (Merot et al., 2004). Using mice selectively deficient in 123 
ERαAF1 or ERαAF2, we previously demonstrated that ERαAF2 is absolutely required for all 124 
nuclear effects of ERα in response to E2 whereas the role of ERαAF1 is highly tissue 125 
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dependent (Abot et al., 2013; Arnal et al., 2013; Billon-Gales et al., 2009; Borjesson et al., 126 
2011). 127 
However, the potential role of the E2 dose on the different biological effects mediated by the 128 
wild-type full length ERα-66 or the AF1/AB domain-deficient ERα has not been evaluated 129 
nor taken into account in most in vivo studies.  130 
In this work, we describe the effect of a 3-week exposure of ovariectomized mice to 3 131 
doses of E2 mimicking metestrus (low dose), proestrus (medium dose) or a supra-132 
pharmacological dose on three major tissues: uterus, vagina and bone. This experimental 133 
paradigm allowed us to precisely compare tissue responses to these 3 doses. An additional 134 
very high dose of E2 was used in transgenic mice harbouring an ERα deleted for AF1 135 
(ERαAF10) and in its littermate wild type mice. 136 
  137 
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2. Material and Methods 138 
2.1 Mice 139 
All procedures involving experimental animals were performed in accordance with the 140 
principles and guidelines established by the National Institute of Medical Research and were 141 
approved by the local Animal Care and Use Committee. The investigation conforms to the 142 
directive 2010/63/EU of the European parliament. Mice were housed in cages in groups of 143 
four to six and kept in a specific pathogen-free and temperature-controlled facility on a 12-144 
hour light to dark cycle. Each experimental group included at least six animals. Female 145 
C57BL/6J mice were purchased from Charles River Laboratories. ERαAF-10 mice were 146 
generated as previously described (Billon-Gales et al., 2009). Mice were anesthetized by 147 
intraperitoneal injection of ketamine (25 mg/kg) and xylazine (10 mg/kg), and ovariectomized 148 
or sham operated at 4 weeks of age, before puberty, to avoid any endogenous estrogen 149 
exposure. After 2 weeks of recovery, mice were implanted subcutaneously with pellets 150 
releasing either vehicle (cholesterol) or various amounts of E2 for 21 days. To deliver 151 
increasing doses of estradiol over prolonged periods of time, various amounts of E2 (E2758 152 
Sigma-Aldrich) and cholesterol (C3045 Sigma-Aldrich) were thoroughly mixed in powder 153 
form and compacted to obtain pellets (20 mg total) that were then implanted subcutaneously 154 
into ovariectomized mice as previously described (Hsieh et al., 1998). Low (LD-E2), medium 155 
(MD-E2), high (HD-E2) and very high (VHD-E2) doses correspond respectively to 156 
weight/weight ratio of E2/cholesterol: 1/20000, 1/2500, 1/250 and 1/25. 157 
2.2 Hormone assays  158 
Plasma E2 levels were assayed by GC/MS, as described previously (Giton et al., 2015) with 159 
minor modifications. Saline water / twice charcoal dextran stripped aged female rabbit serum 160 
(1/1, v/v) was used as the matrix for calibrators and quality control (QC) standards. Briefly, 161 
each sample (serums, calibration standards, quality controls, and blank matrix) was collected 162 
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in an 8 ml borosilicate tube. A spiking solution of deuterated steroid internal standard (IS) (50 163 
µl containing 10 pg of E2-d4, except for blank matrix) (CDN Isotopes, Inc., Point-Claire, 164 
Canada), and 3 ml of 1-chlorobutane were added to each sample. After fast centrifugation, the 165 
upper organic phase was collected on conditioned Hypersep SI 500mg SPE minicolumn 166 
(Thermo Scientific, Rockwood, USA). The column and adsorbed material were then washed 167 
with ethyl acetate / hexane (6 ml; 1/9, v/v).  The second fraction containing E2 was eluted 168 
using ethyl acetate / hexane (4 ml; 1/1, v/v), then evaporated at 60°C to dryness. E2 was 169 
derivatized with pentafluorobenzoyl chloride (PFBC) (103772-1G, Sigma-Aldrich, Steinheim, 170 
Germany). Final extracts were reconstituted in isooctane, then transferred into conical vials 171 
for injection into the GC system (GC-2010 Plus, Shimadzu, Japan) using a 50% 172 
phenylmethylpolysiloxane VF-17MS capillary column (20m x 0.15mm, internal diameter, 173 
0.15µm film thickness) (Agilent Technologies, Les Ulis, France). A TQ8050 (Shimadzu, 174 
Japan) triple quadrupole mass spectrometer equipped with a chemical ionization source and 175 
operating in Q3 single ion monitoring (SIM) mode was used for detection. The reagent gas for 176 
the NCI detection was methane. The GC was performed in pulsed splitless mode with a 1 min 177 
pulsed splitless-time. The oven temperature was initially 150°C for 0.50 min, further 178 
increased to 305°C at 20°C/min and held at 305°C for 3.60 min, and then to 335°C at 179 
30°C/min and held at 335°C for 1.7 min. The injection port and transfer line temperatures 180 
were respectively 290 and 280°C. The flow-rate of helium (carrier gas) was maintained 181 
constant at 0.96 ml/min. The mass spectrometer CI source temperature was 220°C. The 182 
linearity of steroid measurement was confirmed by plotting the ratio of the steroid peak 183 
response / internal standard (IS) peak response to the concentration of E2 for each calibration 184 
standard. Accuracy, target ions, corresponding deuterated internal control, range of detection, 185 
low limit of quantification (LLOQ), and intra & inter assay CVs of the quality control are 186 
reported in Supplemental Table 1. 187 
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2.3 Determination of total plasma cholesterol 188 
Mice were anesthetized and blood samples were collected from the retro-orbital venous 189 
plexus. Total plasma cholesterol was assayed using the CHOD-PAD kit (Horiba ABX, 190 
Montpellier, France). 191 
2.4 Histological analysis  192 
Paraffin-embedded transverse sections (4 µm) from formalin-fixed uterine or vaginal 193 
specimens were stained as previously described with anti–Ki67 (Abot et al., 2013) (RM-9106; 194 
Thermo-scientific). Sections were examined after digitization using a NanoZoomer Digital 195 
Pathology®. To examine the proliferative effects of each treatment, the ratio of Ki67–positive 196 
epithelial cell/total cell number from two microscopic fields of measurement at x20 197 
magnification for each uterine and vaginal section was evaluated. For uterus, the luminal 198 
epithelial height (LEH) of endometrium is the mean of 10 measurements. 199 
2.5 Peripheral quantitative computed tomography (pQCT):  200 
Computerized tomography scans were performed using the pQCT XCT RESEARCH M 201 
(version 4.5B, Norland Stratec, Germany) with a voxel size of 70 µm, as previously described 202 
(Windahl et al., 1999). To measure trabecular volumetric bone marrow density (BMD), the 203 
scan was positioned in the distal metaphysis of the femur at a distance corresponding to 3.4% 204 
of the total femur length in the proximal direction from the distal growth plate. This area 205 
contains trabecular and cortical bone and the trabecular region was defined as the inner 45% 206 
of the total cross-sectional area. The cortical bone parameters were analyzed in the mid-207 
diaphyseal region of femur (Vidal et al., 2000). 208 
2.6 Cell culture and transfection  209 
HeLa, HepG2 and MDA-MB231 cell lines were maintained in DMEM (Invitrogen) 210 
supplemented with 10% fetal calf serum (FCS) (Biowest) and antibiotics (Invitrogen) at 37 ºC in 211 
5% CO2. Transfections were carried out using jetPEI reagent according to manufacturer’s 212 
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instructions (Polyplus transfection). One day before transfection, cells were plated in 24-well 213 
plates at 50% confluence. One hour prior to transfection, the medium was replaced with phenol 214 
red-free DMEM (Invitrogen) containing 2.5% charcoal-stripped FCS (Biowest). Transfection was 215 
carried out with 100 ng of the reporter gene C3-LUC, 100 ng of CMV-βGal internal control and 216 
50 ng of expression vectors pCR-ERα or pCR-ERαAF-10 (Merot et al., 2004). Following an 217 
incubation overnight, cells were treated for 24 h with ethanol (vehicle control) or increasing 218 
concentration of E2. Cells were then harvested and luciferase and β-galactosidase assays were 219 
performed as previously described (Merot et al., 2004).  220 
2.7 Western Blot 221 
One µg of  pCR-ErαWT or pCR-ERαAF10 plasmid were transcribed and translated using 222 
TNT® quick system Promega. Total proteins were separated on a 10% SDS/PAGE gel and 223 
transferred to a nitrocellulose membrane. Primary antibody against ERα was purchased from 224 
Santa Cruz Biotechnology (SP1 ABCAM, 1/500). Revelation was performed using an HRP-225 
conjugated secondary antibody and visualized by enhanced chemoluminescence (ECL) 226 
detection according to the manufacturer’s instructions (Amersham Biosciences/GE 227 
Healthcare), using ChemiDoc Imaging System (Bio-Rad).  228 
2.8 Statistics 229 
Statistics analysis were performed using GraphPad Prism software (version 6, GraphPad 230 
Software, Inc,). To test the different doses of E2, a 1-way ANOVA was performed, followed 231 
by a Fisher's LSD’s multiple comparison post test. To test the respective roles of E2 treatment 232 
and genotype, a 2-way ANOVA was performed. When a significant interaction was observed 233 
between the 2 factors, the difference between genotype and treatment was evaluated by a 234 
Fisher's LSD’s multiple comparison post test. P<0.05 was considered statistically significant. 235 
  236 
11 
 
3. Results 237 
3.1 Dose-response profile to E2 is tissue specific in wild type mice. 238 
 We first studied in vivo the tissue-specific response to different doses of long-term E2 239 
administration (3 weeks) on ovariectomized C57Bl/6 mice (Figure 1A). Plasma estradiol 240 
measurement allowed us to determine the E2/cholesterol ratio that mimicked either metestrus 241 
(low dose, LD-E2 ~1 pg/ml: 3pM) and proestrus (medium dose, MD–E2~10 pg/ml: 30pM) as 242 
previously reported (Nilsson et al., 2015), or a pharmacological dose (high dose HD-E2 ~200 243 
pg/ml: 600pM) (Figure 1B).  In mice on a chow diet, E2 treatment had no impact on body 244 
mass (Figure 1C) or plasma cholesterol content (Figure 1D), regardless of the dose 245 
administered. The pharmacological dose led to high level of E2 especially in view of the 246 
absence of SHBG in mice. Importantly, in mice receiving the high dose of E2, fraction of E2 247 
was converted into estrone (E1) and became detectable in the plasma (Supplementary Table 248 
2). By contrast, the level of estrone in mice supplemented with LD-E2 or MD-E2 is below the 249 
threshold of 10 pg/ml.  250 
Wet weight of the uterus represents the classic endpoint for measuring estrogenicity. 251 
As expected, ovariectomy led to uterine atrophy compared to intact mice, and all E2 doses 252 
increased uterine weight (Figure 2A). The maximal response in terms of weight gain was 253 
reached with the MD-E2, with an attenuated response observed using the HD-E2 (Figure 254 
2A). We next evaluated the level of uterine epithelial proliferation using Ki67 staining. 255 
Epithelial proliferation in response to E2 was maximal at the medium dose, whereas the 256 
pharmacological dose of E2 led to a much lower epithelial proliferation; this represented a 257 
much greater decline than that reflected by uterine weight (Figures 2B and C). Accordingly, 258 
analysis of the height increase of uterine epithelial cells (LEH) as well as stromal proliferation 259 
and density confirmed that the medium dose is required to obtain strongest E2 response 260 
(Table 1). 261 
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Although the evaluation of morphological changes in the vagina is less used to assess 262 
estrogenic exposure in the mouse compared to measurements of uterine parameters, this tissue 263 
is another major target for estrogenic action. A maximal response of vagina in terms of weight 264 
gain was observed using the medium dose of E2, and it then plateaued with the medium or 265 
high dose of E2 (Figure 2D). By contrast, a low dose was sufficient to induce maximal 266 
epithelial proliferation (Figures 2E and F). 267 
 We next analyzed dose response to E2 treatment in bone, a major non-reproductive 268 
target of estrogens. As expected, ovariectomy significantly altered both cortical (Figure 3A) 269 
and trabecular (Figure 3B) bone compartments, but did not impact bone length (Figure 3C). 270 
Treatment with the lowest dose of E2 was sufficient to restore cortical thickness and cortical 271 
bone mineral content (Figure 3A) as well as trabecular bone mineral density (Figure 3B). As 272 
observed in reproductive tissues, the medium dose of E2 induced maximal tissue response 273 
thereafter reaching a plateau, with no additional elevation using the pharmacological dose. 274 
Altogether, these results demonstrated that using pellets designed to release E2 levels 275 
similar to those encountered during metestrus (low dose) and proestrus (medium dose), the 276 
low dose of E2 stimulated 3 target tissues (i.e., vagina, uterus and bone), whereas the medium 277 
dose was necessary to elicit a maximal effect.  278 
3.2 Involvement of ERαAF1 action in mediating E2 response is dose dependent 279 
Our results highlight that response to E2 is dose-dependent, with differences between tissues. 280 
In addition, we previously demonstrated that the role of ERαAF-1 is also tissue-specific, with 281 
a crucial role played in uterus and trabecular bone, but not in cortical bone (Abot et al., 2013; 282 
Borjesson et al., 2011). We first compared the dose response to E2 on an ERE-driven reporter 283 
gene (C3-LUC) in cells expressing either the wild type receptor (ERα66) or the isoform 284 
having a deletion of AF1 (ERαAF10 = ERα46) (Figure 4A) that were introduced into three 285 
different cell lines by transient transfection (Figures 4B-D). Expression vectors encoding 286 
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wild type ERα and ERαAF10 were expressed at similar level after transfection in these 287 
different cell types (Supplementary Figure 1).  In addition to the previously reported cell-288 
specific differences in the transactivation efficiency between both receptors (Merot et al., 289 
2004), we show here the need for higher doses of E2 for ERαAF-10 than for ERαWT to 290 
induce the activity of the reporter gene. The EC50 was about 10 to 100 fold higher for ERαAF-291 
10 than for ERαWT, depending of the cell-type (Figures 4B-D). In addition, even in higher 292 
dose, the maximum response was also much lower using ERαAF-10 (Figure 4B, C), except 293 
for MDA-MB-231 cells (Figure 4D).  294 
We then decided to systematically assess the role of ERαAF-1 in the estrogenic response. To 295 
this end, we used ERαAF10 mice expressing a 49-kDa truncated protein lacking the A domain 296 
and motifs constituting ERα AF-1 in the B domain (Figure 5A) (Billon-Gales et al., 2009). 297 
Since some previous studies have used high doses of estrogens in vivo, until 5 mg E2/ pellet 298 
for 60 day release (Pedram et al., 2014), we have decided to add a very high dose (VHD-E2: 299 
~2000pg/ml i.e 2048 pg/ml ± 242) to evaluate the role of AF-1 function in vivo. We 300 
previously reported that ERαAF10 mice treated with pellets from Innovative Research (0.1 301 
mg E2/pellet: 60 day release) presented a moderate uterine hypertrophy that was essentially 302 
due to stromal edema, with minimal epithelial proliferation compared to WT mice (Abot et 303 
al., 2013). Here, we confirm that no uterine hypertrophy was observed in ERαAF10 mice in 304 
response to LD and MD of E2 (Figure 5B). However, HD-E2 or VHD-E2 induced similar 305 
increase of uterine weight in ERαAF10 and ERαWT mice, demonstrating that the deletion of 306 
the ERα AF1 function can be fully compensated by a 10 to 100-fold increase in the E2 dose 307 
for some parameters such as uterine weigh (Figure 5B). For several other parameters, such as 308 
endometrium epithelial proliferation (Figure 5C) and vagina weight gain (Figure 5D), E2 309 
action was not only shifted rightward but the magnitude of the response was also decreased, 310 
remaining below the full effect observed in control mice, even at the VHD-E2 311 
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pharmacological dose. In addition, we demonstrate for the first time a role of ERαAF1 in 312 
vaginal epithelial proliferation, which as for uterine epithelial proliferation, is highly 313 
dependent of E2 dose (Figure 5E).  314 
Finally, we reconsidered the question of the role of ERαAF1 in bone, and, as previously 315 
described, we demonstrated that ERαAF1 is dispensable for cortical response to E2 regardless 316 
of the dose used, as revealed by the absence of interaction between genotype and E2 treatment 317 
(Figures 6A and B). It should be however noted a significant effect of genotype due to a 318 
smaller cortical thickness and a smaller cortical BMC in ERαAF10 mice, independently on 319 
E2. By contrast, ERαAF1 is required for the increase of bone mineral density (BMD) in 320 
response to E2 in the trabecular compartment regardless of the dose (Figure 6B). We 321 
confirmed that E2 has no impact on bone length in both WT and ERαAF10 mice but 322 
interestingly in ovariectomized mice, bone lengths from ERαAF10 were smaller than in WT 323 
mice, as previously reported in older ERαAF10 mice (Borjesson et al., 2012) (Figure 6C). 324 
Altogether, these data definitely demonstrate that ERαAF1 is necessary for the full E2 325 
response in uterus, vagina and the trabecular bone compartment. However, depending on the 326 
phenotypic feature, ERαAF1 deficiency can be partially or fully overcome by using high E2 327 
levels. 328 
4. Discussion 329 
To understand the physiology of estrogens, as well as to optimize the use of female 330 
sex hormones in medicine, it is crucial to precisely delineate the sensitivity of the tissues to 331 
estrogen levels. It is a common practice to ovariectomize mice to eliminate the main source of 332 
endogenous estrogens, and subsequently to administer E2 exogenously. Subcutaneous 333 
implantation of slow-release pellets is the most convenient and efficient way to deliver 334 
estrogen to mice; it avoids the stress associated with daily subcutaneous injections. In our 335 
study, the low dose of E2 (metestrus level) stimulated vagina, uterus and bone tissues in 336 
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ovariectomized mice, whereas the medium dose (proestrus level) was necessary to elicit a 337 
maximal effect. However, use of a supraphysiological dose (HD-E2) did not confer any 338 
further stimulation compared to the medium dose in these tissues. The HD of E2 even induced 339 
a lesser response than the MD of E2 in the uterus, but not in bone nor in the vagina.  There are 340 
numerous examples of estrogen hormesis, i.e. lowering activity levels while increasing doses, 341 
concerning a wide variety of endpoints, including cerebral (Strom et al., 2011; Strom et al., 342 
2009; Strom et al., 2010), mammary gland differentiation (Vandenberg et al., 2006) and 343 
insulin sensitivity (Gonzalez et al., 2002). High concentrations of E2 can also lead to 344 
increased levels of metabolites, such as estrone (Supplementary Table 2), which can also 345 
influence the biological responses through either dependent or independent ER mechanisms 346 
(Thomas and Potter, 2013).  347 
Remarkably, despite a significant effect on cortical thickness and BMC as well as on 348 
trabecular BMD, E2 even at a very high dose had no impact on bone length in our 349 
experimental conditions. This result differs from previous studies that reported a reduced bone 350 
length and growth plate width using high dose of E2 in older mice (Borjesson et al., 2012; 351 
Borjesson et al., 2010). These apparent discrepancies underline the importance of the age of 352 
ovariectomy, age of mouse studied, and timing of E2 supplementation.  353 
 E2 effects are mediated by hormone binding to ERα, ERβ or GPR30 (Miller et al., 354 
2017). ERα also exists as two isoforms, designated ERα66 and ERα46, based on their 355 
respective molecular weight, and both isoforms were reported to regulate E2-mediated 356 
proliferation in the mouse uterus (Abot et al., 2013). The expression of ERα46 in the rat 357 
uterus was demonstrated even before the use of antibodies against ERα  (Faye et al., 1986).  358 
Importantly, we recently demonstrated that ERα46 is frequently and sometimes abundantly 359 
expressed in ERα-positive breast tumors, but the mechanisms of its generation as well as 360 
pathophysiological significance of its expression are essentially unknown (Chantalat et al., 361 
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2016). Furthermore, the specific signalling events associated with this AF1-deficient isoform 362 
as well as its interactions with the full length ERα66 remain unclear. Given the complexity of 363 
estrogen-mediated actions, which goes far beyond the single-receptor situation on which the 364 
linear dose-response model is based, it is not surprising that E2 can elicit hormetic responses. 365 
In particular, varied affinities for distinct receptors having different intrinsic activity levels 366 
would essentially lead to a “mixture” effect, where the summation of their individual dose-367 
response curves would lead to composite behaviour that could be non-monotonic (Miller et 368 
al., 2017).  In particular, we previously proposed that ERα46 counteracts ERα66 on E2-369 
induced cell proliferation  (Abot et al., 2013; Penot et al., 2005).  370 
The structural difference between ERα66 and ERα46, according to our current 371 
knowledge, resides mainly in the absence of AF1 in ERα46 (Chantalat et al., 2016). 372 
Accordingly, both receptors exhibit different transactivation efficiencies in a cell-specific 373 
manner (Merot et al., 2004). It has been proposed that ERα46 could have a repressive role in 374 
AF1-permissive contexts through interference with ERα66 binding to DNA (Penot et al., 375 
2005). The present study deepens the comparison between both ERα forms by revealing a 376 
major difference in their transcriptional sensitivity to the dose of E2. To reach the maximal 377 
level of ligand-dependent transcriptional activity, ERα46 requires an E2 dose 10 to 100 times 378 
higher than does ERα66. Several studies have shown that N-terminal truncated forms of ERα, 379 
including ERα46, have an affinity for E2 which is similar to that found for the wild-type 380 
ERα66, indicating that the hormone binding domain is able to function independently of the 381 
N-terminal half of the ER (Kumar et al., 1986; Carlson et al., 1997; Lin et al., 2013). 382 
However, differences in ERα binding to DNA and in coactivator and/or corepressor 383 
recruitment could explain the distinctively lower sensitivity of ERα46 versus ERα66 to the 384 
dose of E2. We previously reported that although the qualitative overall recruitment of 385 
cofactors is quite similar between ERα46 and ERα66, there is a quantitative differential 386 
17 
 
modulation with some preference for cofactor binding to ERα66 over ERα46 (Chantalat et al., 387 
2016). ERα46 is also able to recruit transcriptional repressors in a ligand-independent manner 388 
(Metivier et al., 2004). In accordance with the specific binding of coregulators, we reported 389 
that some genes were specifically regulated by either the ERα46 or ERα66 isorforms, 390 
demonstrating that the absence of ERαAF1 affects specific transcriptional programs rather 391 
than leading to an overall decreased activity (Chantalat et al., 2016) . 392 
Using mice harbouring an ERα deleted for AF1 (ERαAF10), we previously 393 
demonstrated that ERαAF1 is necessary to induce uterine hypertrophy, suggesting that 394 
ERα46 is not able to mediate E2 responses in uterus (Abot et al., 2013). Here, we 395 
demonstrate that with a HD of E2, the increase in uterine weight is similar between ERαAF10 396 
and ERαWT, although an attenuated response is observed in terms of epithelial proliferation. 397 
By contrast, physiological LD or MD doses of E2 leading to levels encountered during the 398 
estrous cycle were unable to induce a uterine response in ERαAF10 mice in contrast to 399 
ERαWT mice.  These results demonstrate that the involvement of ERαAF1 in the E2 400 
response is highly dependent on ligand dose, and that different signalling pathways regulate 401 
epithelial proliferation and uterine weight gain. Similarly, the response to E2 in vagina and 402 
trabecular bone are dependent of ERαAF-1, since this response is not only shifted rightward 403 
but also decreased in intensity, suggesting that these tissues can be used as an index of 404 
ERαAF-1-dependent estrogenicity.  405 
There is also evidence that amino acid phosphorylation located in the ERαAF-1 406 
domain, regulates numerous aspects of ERα function, including protein stability, hormone 407 
binding, receptor dimerization, DNA binding, protein-protein interactions, and transcription 408 
activity (Orti et al., 1992; Lannigan, 2003; Weigel and Moore, 2007). In particular, Ser118 409 
has been implicated in ERα mediated transcriptional regulation since a partial or complete 410 
18 
 
attenuation of E2-induced transcription has been observed in ERαS118A transfected cells 411 
(Ali et al., 1993; Duplessis et al., 2011). Appropriate transgenic mouse studies should be 412 
developed to determine the importance of ERα Ser118 phosphorylation in vivo. 413 
 414 
5. Conclusion 415 
We describe here the dose-effect of E2 on sexual targets and bone thanks to a simple, reliable 416 
and unexpansive slow release device. Our results demonstrate that the estrogenic effect on 417 
tissues is highly dependent on the dose used. Although the precise role of ERαAF1 both in 418 
physiology and in pathology remains to be clarified, the present work reveals that ERαAF1 419 
provides an important layer of regulation through the sensitization of the response to 420 
estrogens. The role of ERαAF1 can be even more spectacular in the action of some selective 421 
ER modulators (SERMs) (Arao and Korach, 2019). For instance, tamoxifen selectively 422 
activates ERαAF1, and this activation is required for the beneficial effects of this SERM on 423 
arteries (Fontaine et al., 2013) and metabolism (Guillaume et al., 2017), while at the same 424 
time it prevents the recurrence of breast cancer. Whereas antagonist activity of tamoxifen is 425 
essentially through the ERαAF2 blockade, molecular mechanism of its partial agonist activity 426 
that involved ERαAF1 activation is not fully understood (Arao and Korach, 2019). Here, we 427 
report that importance of ERαAF1 domain in estrogenic response depend on both considered 428 
cell type/ tissues and ligand dose, two parameters which could be determinant in the agonist 429 
activity of E2 or SERM that control ERαAF-1-mediated physiological response. 430 
 431 
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FIGURE LEGEND 588 
Figure 1: Plasma estradiol (E2) and cholesterol concentrations in mice implanted with 589 
E2/cholesterol pellets. 590 
Pellets releasing low dose (LD), medium dose (MD) or high dose (HD) of E2 were implanted 591 
subcutaneously into ovariectomized mice for a period of 3 weeks (A).  Plasma E2 (B), body 592 
weight (C) and cholesterol content (D) of the mice were evaluated.  593 
Figure 2: E2 dose response analysis of uterine and vaginal parameters 594 
Pellets releasing low dose (LD), medium dose (MD) or high dose (HD) of E2 were implanted 595 
subcutaneously into ovariectomized mice for a period of 3 weeks and uterus (A, B, C) and 596 
vagina (D, E, F) were analyzed. Uterine (A) and vagina (D) weight. Percentage of uterine (B) 597 
and vagina (E) Ki67-positive epithelial cells. Results are expressed as means ± SEM. To test 598 
effect of E2 exposure, one-way ANOVA and a Fisher's LSD’s post test were performed (E2 599 
exposure versus placebo *P < 0.05, ***P < 0.001, difference in E2 concentration †††P<0.001 600 
n=10/12 mice/group). Representative Ki-67 detection in transverse uterus (C) and vagina (F) 601 
sections. 602 
Figure 3: E2 dose response analysis of bone parameters 603 
Pellets releasing low dose (LD), medium dose (MD) or high dose (HD) of E2 were implanted 604 
subcutaneously into ovariectomized mice for a period of 3 weeks and femurs were analyzed. 605 
Cortical thickness and cortical bone mineral content (BMC) (A) in the mid-diaphyseal part of 606 
femur. Trabecular bone mineral density (BMD) in the distal metaphyseal part of femur (B) 607 
and Bone length (C). Results are expressed as means ± SEM. To test effect of E2 exposure, 608 
one-way ANOVA and a Fisher's LSD’s post test were performed (E2 exposure versus placebo 609 
**P < 0.01, ***P < 0.001, difference in E2 concentration †††P<0.001, n=6/7 mice/group). 610 
Figure 4: Dose response of E2 transcriptional activity in cultured cells expressing ERα66 611 
or ERα46. 612 
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Schematic representation of the wild-type ERα66 (ERαAF1+/+) and ERα (ERαAF10) isoforms 613 
and expression of these isoforms obtained from in vitro translation pCR-ERαWT or pCR-614 
ERαAF10 vectors performed with the TNT Coupled Reticulocyte Lysate System (A). HepG2 615 
(B), HeLa (C) and MDA-MB231 (D) cells were transiently transfected with the C3-Luc 616 
reporter constructs in the presence of pCR-ERαWT, pCR-ERαAF10, or empty pCR vectors. 617 
Cells were treated with the indicated dose of E2 or vehicle (Ctrl) for 24 h. Normalized 618 
luciferase activities were expressed as fold increase above values measured with empty pCR 619 
and vehicle. Data correspond to the mean values ± SEM of at least three separate transfection 620 
experiments. Two-way ANOVA followed by Fisher's LSD’s multiple comparison test were 621 
performed (ERαAF1+/+ versus ERαAF10:  *P < 0.05, **P < 0.01, ***P < 0.001). 622 
Figure 5: The role of ERαAF1 in uterine and vagina is dependent of E2 dose 623 
Schematic representation of the wild-type ERαAF1+/+ and ERαAF10 mice constructs (A).  624 
Pellets releasing low dose (LD), medium dose (MD), high dose (HD) or very high dose 625 
(VHD) of E2 were implanted subcutaneously into ERαAF10 ovariectomized mice during 3 626 
weeks. Uterus (B, C) and vagina (D, E) were analyzed. Uterine (B) and vagina (D) weight. 627 
Percentage of uterine (C) and vagina (E) Ki67-positive epithelial cells. Representative Ki-67 628 
detection in transverse uterus sections. Results are expressed as means ± SEM. Two-way 629 
ANOVA followed by Fisher's LSD’s multiple comparison test were performed (ERαAF1+/+ 630 
versus ERαAF10:  *P < 0.05, **P < 0.01, ***P < 0.001, n=6/8 mice/group). 631 
 632 
  633 
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Figure 6: E2 dose response analysis of trabecular and cortical bone parameters in wild-634 
type ERαAF1+/+ and ERαAF10 mice.  635 
Pellets releasing low dose (LD), medium dose (MD), high dose (HD) or very high dose 636 
(VHD) of E2 were implanted subcutaneously to ERαAF10 ovariectomized mice for a period 637 
of 3 weeks and femurs were analyzed.  Cortical thickness and cortical bone mineral content 638 
(BMC) in the mid-diaphyseal part of femur. 2-way ANOVA test revealed no significant 639 
interaction, the overall effect of the treatment and genotype was analyzed (A). Trabecular 640 
bone mineral density (BMD) in the distal metaphyseal part of femur (B) and Bone length (C). 641 
Results are expressed as means ± SEM. Since two-way ANOVA test revealed a significant 642 
interaction between the 2 factors (E2 exposure and genotype), a Fisher's LSD’s multiple 643 
comparison test were performed (ERαAF1+/+ versus ERαAF10: **P < 0.01, ***P < 0.001, 644 
n=6/8 mice/group) (B, C). 645 
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Table 1: Analysis of uterine parameters in C57Bl/6 mice
OVX LD-E2 MD-E2 HD-E2
Uterine LEH
(µm) 12.1 +/- 0.6 20.2 +/- 1.2 ** 37.6 +/- 1.9 *** 40.5 +/- 2.1 ***
Uterine Stromal
Density 257 +/- 1.14 116.7 +/- 44.6 *** 87 +/- 35.5 *** 72.7 +/- 34.5 ***
Uterine Stromal
proliferation
(%Ki67positive cells) 
0.3 +/- 0.5 8 +/- 5.6 42.1 +/- 11 *** 21.6 +/- 8 ***
Results are expressed as means ± SEM. To test the respective roles of each treatment, one-way ANOVA 
and a Fisher's LSD’s post test were performed (treatment versus placebo **, P < 0.01, ***, P < 0.001)
LLOQ : low limit of quantification; QC : quality control
Supplementary Table 1 : GC/MS plasma analytical control validation 
Accucary
(%)
Analyte Target ion 
analyte /IS 
(amu)
Range 
(pg/ml)
R2
Mean (pg/ml) 17 runsI
Intra- & Inter assay CVs (%)
94-107 E2 660/664
0.2- 56.0
0.9994
LLOQ Low QC Middle QC High QC
0.22
17.3 -19.6
2.87
2.9-4.2
6.07
2.6-3.7
12.88
2.3-3.33
Supplementary Table 2: GC/MS plasma Estrone (E1) dosage
OVX LD-E2 MD-E2 HD-E2
Estrone (E1) < 10pg/ml < 10pg/ml < 10pg/ml 22,5 +/- 5,4
Results are expressed as means ± SEM. 
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Supplementary Figure 1: Western blot analysis was performed on an
equal amount of cellular extracts prepared from cells transfected with
empty vectors (lane 1) expression vectors encoding wild type (lane 2),
or ERαAF10 mutant (lane 3).
HIGHLIGHTS          
• Some biological response to E2 displays biphasic dose relationship. 
• ERαAF1 plays a key sensitizing role in ERα activity. 
• Differences and even contradictory conclusions could be explained by 
differences of E2 doses. 
 
